CANCER:

Pancreatic Ductal Adenocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Pancreatic Cancer (367)

Pancreatic Adenocarcinoma (61)

Pancreatic Cancer (367)

Pancreatic Adenocarcinoma (61)

›

No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	SBP-101 Sensitive: B - Late Trials SBP-101 Sensitive : B	SBP-101 Sensitive: B - Late Trials SBP-101 Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	gemcitabine Sensitive: B - Late Trials gemcitabine Sensitive : B	gemcitabine Sensitive: B - Late Trials gemcitabine Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	gemcitabine + capecitabine Sensitive: B - Late Trials gemcitabine + capecitabine Sensitive : B	gemcitabine + capecitabine Sensitive: B - Late Trials gemcitabine + capecitabine Sensitive : B
CCL11 overexpression	Pancreatic Ductal Adenocarcinoma	CCL11 overexpression	Pancreatic Ductal Adenocarcinoma	tertomotide Sensitive: B - Late Trials tertomotide Sensitive : B	tertomotide Sensitive: B - Late Trials tertomotide Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	LSTA1 Sensitive: B - Late Trials LSTA1 Sensitive : B	LSTA1 Sensitive: B - Late Trials LSTA1 Sensitive : B
KRAS wild-type	Pancreatic Ductal Adenocarcinoma	KRAS wild-type	Pancreatic Ductal Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: B - Late Trials gemcitabine + albumin-bound paclitaxel Sensitive : B	gemcitabine + albumin-bound paclitaxel Sensitive: B - Late Trials gemcitabine + albumin-bound paclitaxel Sensitive : B
KRAS wild-type	Pancreatic Ductal Adenocarcinoma	KRAS wild-type	Pancreatic Ductal Adenocarcinoma	5-fluorouracil + oxaliplatin Sensitive: B - Late Trials 5-fluorouracil + oxaliplatin Sensitive : B	5-fluorouracil + oxaliplatin Sensitive: B - Late Trials 5-fluorouracil + oxaliplatin Sensitive : B
BRCA2 mutation	Pancreatic Ductal Adenocarcinoma	BRCA2 mutation	Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
ATM mutation	Pancreatic Ductal Adenocarcinoma	ATM mutation	Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
BRCA1 mutation	Pancreatic Ductal Adenocarcinoma	BRCA1 mutation	Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
KRAS mutation	Pancreatic Ductal Adenocarcinoma	KRAS mutation	Pancreatic Ductal Adenocarcinoma	pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria pembrolizumab + trametinib Sensitive : C2	pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria pembrolizumab + trametinib Sensitive : C2
HGF-H	Pancreatic Ductal Adenocarcinoma	HGF-H	Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C3 – Early Trials FOLFIRINOX Resistant : C3	FOLFIRINOX Resistant: C3 – Early Trials FOLFIRINOX Resistant : C3
MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PALB2 mutation	Pancreatic Ductal Adenocarcinoma	PALB2 mutation	Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
BRCA1 mutation + BRCA2 mutation	Pancreatic Ductal Adenocarcinoma	BRCA1 mutation + BRCA2 mutation	Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
FANCF mutation	Pancreatic Ductal Adenocarcinoma	FANCF mutation	Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
MSH2 mutation	Pancreatic Ductal Adenocarcinoma	MSH2 mutation	Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
BRCA2 mutation	Pancreatic Ductal Adenocarcinoma	BRCA2 mutation	Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
BRCA1 mutation	Pancreatic Ductal Adenocarcinoma	BRCA1 mutation	Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
DDR	Pancreatic Ductal Adenocarcinoma	DDR	Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
C3M/PRO-C3 ratio elevation	Pancreatic Ductal Adenocarcinoma	C3M/PRO-C3 ratio elevation	Pancreatic Ductal Adenocarcinoma	PEGPH20 Sensitive: C3 – Early Trials PEGPH20 Sensitive : C3	PEGPH20 Sensitive: C3 – Early Trials PEGPH20 Sensitive : C3
PALB2 mutation	Pancreatic Ductal Adenocarcinoma	PALB2 mutation	Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3
BRCA2 mutation	Pancreatic Ductal Adenocarcinoma	BRCA2 mutation	Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3
BRCA1 mutation	Pancreatic Ductal Adenocarcinoma	BRCA1 mutation	Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3
GATA6 underexpression	Pancreatic Ductal Adenocarcinoma	GATA6 underexpression	Pancreatic Ductal Adenocarcinoma	leucovorin calcium Resistant: C3 – Early Trials leucovorin calcium Resistant : C3	leucovorin calcium Resistant: C3 – Early Trials leucovorin calcium Resistant : C3
GATA6 underexpression	Pancreatic Ductal Adenocarcinoma	GATA6 underexpression	Pancreatic Ductal Adenocarcinoma	5-fluorouracil Resistant: C3 – Early Trials 5-fluorouracil Resistant : C3	5-fluorouracil Resistant: C3 – Early Trials 5-fluorouracil Resistant : C3
GATA6 expression	Pancreatic Ductal Adenocarcinoma	GATA6 expression	Pancreatic Ductal Adenocarcinoma	gemcitabine Resistant: C3 – Early Trials gemcitabine Resistant : C3	gemcitabine Resistant: C3 – Early Trials gemcitabine Resistant : C3
LAMC2 overexpression	Pancreatic Ductal Adenocarcinoma	LAMC2 overexpression	Pancreatic Ductal Adenocarcinoma	gemcitabine Resistant: C3 – Early Trials gemcitabine Resistant : C3	gemcitabine Resistant: C3 – Early Trials gemcitabine Resistant : C3
ATM mutation	Pancreatic Ductal Adenocarcinoma	ATM mutation	Pancreatic Ductal Adenocarcinoma	durvalumab + gemcitabine + CP-675206 Sensitive: C3 – Early Trials durvalumab + gemcitabine + CP-675206 Sensitive : C3	durvalumab + gemcitabine + CP-675206 Sensitive: C3 – Early Trials durvalumab + gemcitabine + CP-675206 Sensitive : C3
ARID1A mutation	Pancreatic Ductal Adenocarcinoma	ARID1A mutation	Pancreatic Ductal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3

Pancreatic Ductal Adenocarcinoma

Associations(91)

Associations
(91)